Dados do Trabalho

Título

Glycemic control and clinical outcomes in hospitalized patients with COVID-19

Objetivo

This study aimed to evaluate the association of glycemic control with clinical outcomes and mortality in hospitalized patients with COVID 19.

Métodos

This was a retrospective study that evaluated a cohort of COVID 19 adult patients admitted to intensive care unit (ICU) in a private hospital from march to December 2020.

Resultados

92 cases of moderate to severe COVID 19 were analyzed with mean age= 76.1 +/- 14.4 years. At admission, prognostic scores were SOFA= 4.0 (1- 14), SAPS 3= 55.4 +/- 13.8, SAPS mortality risk= 26.67% (9.7-42.5); 42.4% of the patients had diabetes (DM) and 64.1% had hyperglycemia (> 180 mg/dl). During hospital stay, the rate of hyperglycemia > 180mg/dl was 20%, > 300mg/dl was 1.47% and of hypoglycemia < 70 mg/dl was 1.56%; hyperglycemia was observed in 42.5% and 57.6% of patients with and without DM (respectively, p= 0.039) and 34.8% of the patients were treated with intravenous insulin. Hyperglycemia was associated with SAPS mortality score (p= 0.048) and age (p=0.043), while hypoglycemia was related to age (p=0.005), SOFA (p=0.028), SAPS 3 (p=0.031) and SAPS mortality score (p=0.029). Mean hospital length of stay = 18 days (1- 279), mortality rate = 38%, use of mechanical ventilation= 56.5%; use of vasoactive drugs = 58.7% and dialytic support= 15.2%. Hyperglycemia was significantly related to mortality (p=0.013), mechanical ventilation (p=0.009) and vasoactive drugs (p=0.043).

Conclusão

Poor glycemic control was related to increased morbidity and mortality in hospitalized patients with COVID 19.